embryoid

In addition, "Interestingly" the embryoid body formation was faster than the control cell line.

The morphological examination showed the formation of embryoid body formation by Day-6.

KIAA1109 is expressed in all stages of development from embryoid body to adult, except in infants.

Embryoid bodies (EBs) are three-dimensional aggregates of pluripotent stem cells.

SPTBN5 is highly expressed in embryoid bodies.

The lower dose of TSA allowed the formation of some embryoid body formation.

The 10nM TSA treated cells failed to form the embryoid body by Day-6 as observed in the control cell line.

Embryoid bodies are a common in vitro pluripotency test for stem cells and their size needs to be controlled to induce directed differentiation to specific lineages.

High throughput formation of uniform sized embryoid bodies with microwells and microfluidics allows easy retrieval and more importantly, scale up for clinical contexts.

Embryonic stem cells were also analyzed morphologically to observe the formation of embryoid body formation as one of the measures of cell differentiation.

These cells grew in culture and demonstrated pluripotent characteristics, as demonstrated by the ability to form teratomas, differentiate in vitro, and form embryoid bodies.

By contrast, mesoderm development invariably accompanies endoderm development in embryoid bodies derived from human ES cells or embryonic germ cells [31,32,33].

Loss of CD47 allows sustained proliferation of primary murine endothelial cells and enables these cells to spontaneously reprogram to form multipotent embryoid body-like clusters.

In P19 cells, using non-toxic concentration of drugs to aggregated embryoid body cells can induce P19 cells differentiating into specific cell lines based on different drugs.

Polyembryoma has features of both yolk sac tumour and undifferentiated teratoma/embryonal carcinoma, with a characteristic finding of embryoid bodies lying in a loose mesenchymal stroma.

In order to analyze the process of HDAC knockout mouse in detail, the knockout mice embryonic stem cells were used to generate embryoid bodies.

Using aggregates of differentiating mouse embryonic stem cells called embryoid bodies, the authors plated cells in the differentiation timeline just prior to the arise of hematopoietic cells.

The continued culture of HDAC1 knockout embryonic stem cells showed that the embryoid bodies formed became irregular and reduced in size rather than uniformly spherical as in normal mice.

This can occur "in vitro" in embryoid bodies (EB) derived from embryonic stem cells; this process in EB is similar to "in vivo" vasculogenesis.

The microscopic features include: indistinct cell borders, mitoses, a variable architecture (tubulopapillary, glandular, solid, embryoid bodies - ball of cells surrounded by empty space on three sides), nuclear overlap, and necrosis.

Actively controlling embryoid body cell organization and architecture can also direct stem cell differentiation using microfluidic gradients of endoderm-, mesoderm- and ectoderm-inducing factors, as well as self-renewal factors.

Evans and Kaufman showed that the cells grown out from these cultures could form teratomas and embryoid bodies, and differentiate in vitro, all of which indicating that the cells are pluripotent.

Differentiation in stem cells is dependent on many factors, including soluble and biochemical factors, fluid shear stress, cell-ECM interactions, cell-cell interactions, as well as embryoid body formation and organization.

DPPSCs were able to form both embryoid bodies-like structures (EBs) in vitro and teratoma-like structures that contained tissues derived from all three embryonic germ layers when injected in nude mice.

For differentiation to occur, the human embryonic stem cell line is removed from the supporting cells to form embryoid bodies, is co-cultured with a serum containing necessary signals, or is grafted in a three-dimensional scaffold to result.